Creating new treatments for liver damage caused by acetaminophen overdose
Official title: Development of heparan sulfate-based therapeutics to treat inflammatory diseases
Funded at Glycan Therapeutics Corporation · NIH-10922837 · Data updated 2026-11-12
This study is testing a new treatment called GLY-202 for people who have liver damage from taking too much acetaminophen, especially those who come in for help later than usual, to see if it can work better than current options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glycan Therapeutics Corporation NIH-funded |
| Lab location | 1 site (Raleigh, UNITED STATES) |
| Project start | September 14, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,463,275 |
| NIH project number | 5R44GM144019-03 |
| Project ID | NIH-10922837 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced an acetaminophen overdose and are at risk of acute liver failure.
✕Less likely to help
Patients who have not ingested acetaminophen or those who present for treatment within the effective window for existing antidotes may not benefit from this research.
What this research studies
This research focuses on developing a new synthetic heparan sulfate oligosaccharide, GLY-202, aimed at treating patients who experience liver toxicity from acetaminophen overdose. The project seeks to improve upon existing treatments by providing an effective option for patients who present late for treatment, as current antidotes are only effective within a limited time frame. The research involves optimizing the synthesis of GLY-202 to ensure it can be produced more efficiently and cost-effectively, while also conducting necessary studies to assess its safety and effectiveness. Patients who suffer from acute liver failure due to acetaminophen overdose may benefit from this innovative approach.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from liver failure due to acetaminophen overdose, potentially reducing the need for liver transplants.
How similar studies have gone: While the approach of using synthetic heparan sulfate oligosaccharides is innovative, similar strategies in treating liver toxicity have shown promise in preliminary studies.
Where this research is happening
-
Glycan Therapeutics Corporation
Raleigh, United States Active
Researchers
- Principal investigator: Wang, Zhangjie — Glycan Therapeutics Corporation
- Study coordinator: Wang, Zhangjie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.